More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3853448
EPS
-2.17
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.090871
Previous close
$0.63
Today's open
$0.61
Day's range
$0.56 - $0.64
52 week range
$0.50 - $4.35
show more
CEO
Stacy R. Lindborg
Employees
20
Headquarters
Lawrenceville, NJ
Exchange
NASDAQ Capital Market
Shares outstanding
6487286
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
GlobeNewsWire • Nov 12, 2026

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
GlobeNewsWire • Nov 6, 2026

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m.
GlobeNewsWire • Nov 2, 2026

IMUNON Announces Strategic Sale of ThermoDox®
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
GlobeNewsWire • Oct 21, 2026

IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.
GlobeNewsWire • Oct 8, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company's newly designated, non-convertible Series B Preferred Stock.
GlobeNewsWire • Sep 29, 2026

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer.
GlobeNewsWire • Sep 24, 2026

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Seeking Alpha • Sep 23, 2026

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
GlobeNewsWire • Sep 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Imunon Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.